Most Recent Articles by Brandon May
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
When deviating from published guidelines, physicians must ensure their recommendations are based on justified belief, not personal bias.
Research findings suggest the need for greater adherence to a standardized set of policies aimed at improving transparency among clinical trial funders.
There are substantial limitations to depending only on institutional investigations of scientific misconduct.
More Articles by Brandon May
Dermatology Advisor Articles
- Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies
- Strong Bidirectional Association Found Between Depression and Alopecia
- Immunosuppressants Associated With Unsatisfactory Outcomes in Atopic Dermatitis
- Molecular Profiles Vary With Age in Atopic Dermatitis
- Johnson & Johnson to Provide Drug Prices in TV Ads
- Aesthetic-Only Neurotoxin Jeuveau Gets FDA Approval
- Turmeric Polyherbal Supplement May Help Reduce Facial Erythema
- Dupilumab Impacts Symptoms of Atopic Dermatitis in Real-Life Setting
- HIDRAdisk Is a Validated Visual Tool to Assess Hidradenitis Suppurativa Burden
- Thermography Helps Diagnose Allergic vs Irritant Contact Dermatitis